Martin Ebner

Title: Martin Ebner: Innovator in Binding Molecules

Introduction

Martin Ebner is a notable inventor based in Oxon, GB. He has made significant contributions to the field of biotechnology, particularly in the development of binding molecules that have potential applications in treating malignant diseases. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Martin Ebner holds a patent related to binding molecules that comprise T cell receptor (TCR) variable domains. This invention specifically focuses on molecules that can bind to a PRAME peptide-HLA complex, particularly the PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The implications of this invention are profound, as it relates to the treatment of various malignant diseases, highlighting the potential for therapeutic advancements in oncology.

Career Highlights

Throughout his career, Martin has been associated with Immunocore Limited, a company that specializes in developing innovative therapies for cancer and other diseases. His work at Immunocore has positioned him as a key player in the biotechnology sector, contributing to groundbreaking research and development efforts.

Collaborations

Martin collaborates with talented individuals such as Jakub Jaworski and Kate Atkin. These partnerships enhance the innovative environment at Immunocore, fostering creativity and the exchange of ideas that drive progress in their research initiatives.

Conclusion

In summary, Martin Ebner is a distinguished inventor whose work in binding molecules has the potential to revolutionize treatments for malignant diseases. His contributions to Immunocore Limited and collaborations with fellow researchers underscore his commitment to advancing medical science.